Literature DB >> 2211718

A far upstream element stimulates c-myc expression in undifferentiated leukemia cells.

M I Avigan1, B Strober, D Levens.   

Abstract

A sensitive exonuclease assay revealed multiple sites for interaction, in vitro, of sequence specific factors with c-myc upstream elements. At one site, more than 1500 base pairs upstream of the c-myc promoter P1, binding activity was lost as dimethyl sulfoxide (Me2SO) induced shut-off of c-myc expression in HL-60 and U-937 leukemia cells. The disappearance of other specific binding activities was not noted. In addition, the binding activity was noted to be cell-line specific. The sequence binding the Me2SO-regulated factor was precisely located allowing confirmation of the temporal pattern of regulation by electrophoretic mobility shift analysis. Because the binding activity was most abundant before the decrease of c-myc expression during differentiation, it was inferred that the far upstream element (FUSE) served a positive role, potentiating c-myc expression. A 4-base pair deletion which eliminated binding to FUSE also reduced expression of a transfected, chimeric c-myc-CAT gene in untreated, but not in Me2SO-treated U-937 cells. FUSE and its binding protein may contribute to cell line- and differentiation-specific modes of c-myc regulation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2211718

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  56 in total

1.  Loss of FBP function arrests cellular proliferation and extinguishes c-myc expression.

Authors:  L He; J Liu; I Collins; S Sanford; B O'Connell; C J Benham; D Levens
Journal:  EMBO J       Date:  2000-03-01       Impact factor: 11.598

2.  Interpretation of NMR relaxation properties of Pin1, a two-domain protein, based on Brownian dynamic simulations.

Authors:  Pau Bernadó; Miguel X Fernandes; Doris M Jacobs; Klaus Fiebig; José García de la Torre; Miquel Pons
Journal:  J Biomol NMR       Date:  2004-05       Impact factor: 2.835

3.  Demonstration that drug-targeted down-regulation of MYC in non-Hodgkins lymphoma is directly mediated through the promoter G-quadruplex.

Authors:  Robert V Brown; Forest L Danford; Vijay Gokhale; Laurence H Hurley; Tracy A Brooks
Journal:  J Biol Chem       Date:  2011-09-28       Impact factor: 5.157

4.  Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma.

Authors:  Christopher J Stasik; Hiroaki Nitta; Wenjun Zhang; Charles H Mosher; James R Cook; Raymond R Tubbs; Joseph M Unger; Tracy A Brooks; Daniel O Persky; Sarah T Wilkinson; Thomas M Grogan; Lisa M Rimsza
Journal:  Haematologica       Date:  2010-04       Impact factor: 9.941

5.  Non-transmissible Sendai virus vector encoding c-myc suppressor FBP-interacting repressor for cancer therapy.

Authors:  Kazuyuki Matsushita; Hideaki Shimada; Yasuji Ueda; Makoto Inoue; Mamoru Hasegawa; Takeshi Tomonaga; Hisahiro Matsubara; Fumio Nomura
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

6.  Multiple single-stranded cis elements are associated with activated chromatin of the human c-myc gene in vivo.

Authors:  G A Michelotti; E F Michelotti; A Pullner; R C Duncan; D Eick; D Levens
Journal:  Mol Cell Biol       Date:  1996-06       Impact factor: 4.272

Review 7.  Alternative splicing of DNA damage response genes and gastrointestinal cancers.

Authors:  Bahityar Rahmutulla; Kazuyuki Matsushita; Fumio Nomura
Journal:  World J Gastroenterol       Date:  2014-12-14       Impact factor: 5.742

Review 8.  FUBP/KH domain proteins in transcription: Back to the future.

Authors:  Leonie M Quinn
Journal:  Transcription       Date:  2017-02-16

9.  NF-kappa B sites function as positive regulators of expression of the translocated c-myc allele in Burkitt's lymphoma.

Authors:  L Ji; M Arcinas; L M Boxer
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

Review 10.  The role of supercoiling in transcriptional control of MYC and its importance in molecular therapeutics.

Authors:  Tracy A Brooks; Laurence H Hurley
Journal:  Nat Rev Cancer       Date:  2009-11-12       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.